158 related articles for article (PubMed ID: 38055053)
21. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
22. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
[TBL] [Abstract][Full Text] [Related]
23. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
Basse C; Chabanol H; Bonte PE; Fromantin I; Girard N
Lung Cancer; 2022 Nov; 173():116-123. PubMed ID: 36198244
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Shinohara A; Ikeda M; Okuyama H; Kobayashi M; Funazaki H; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Ichida Y; Takahashi K; Okusaka T; Saitoh S
Am J Clin Dermatol; 2015 Jun; 16(3):221-9. PubMed ID: 25687689
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
Wehler TC; Graf C; Möhler M; Herzog J; Berger MR; Gockel I; Lang H; Theobald M; Galle PR; Schimanski CC
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1667-72. PubMed ID: 23918349
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Iwasaku M; Uchino J; Chibana K; Tanzawa S; Yamada T; Tobino K; Uchida Y; Kijima T; Nakatomi K; Izumi M; Tamiya N; Kimura H; Fujita M; Honda R; Takumi C; Yamada T; Kaneko Y; Kiyomi F; Takayama K
Cancer Med; 2023 Jul; 12(14):15117-15127. PubMed ID: 37269194
[TBL] [Abstract][Full Text] [Related]
27. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
Kim YS; Ji JH; Oh SY; Lee S; Huh SJ; Lee JH; Song KH; Son CH; Roh MS; Lee GW; Lee J; Kim ST; Kim CK; Jang JS; Hwang IG; Ahn HK; Park LC; Oh SY; Kim SG; Lee SC; Lim DH; Lee SI; Kang JH
Oncologist; 2020 Jan; 25(1):e186-e193. PubMed ID: 31492766
[TBL] [Abstract][Full Text] [Related]
29. Reducing Acneiform Rash Induced by EGFR Inhibitors With Honeysuckle Therapy: A Prospective, Randomized, Controlled Study.
Liu Z; Tian T; Wang B; Lu D; Ruan J; Shan J
Front Pharmacol; 2022; 13():835166. PubMed ID: 35250582
[No Abstract] [Full Text] [Related]
30. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part).
Kikuchi K; Yamazaki N; Nozawa K; Fukuda H; Shibata T; Machida R; Hamaguchi T; Takashima A; Shoji H; Boku N; Takatsuka S; Takenouchi T; Nishina T; Yoshikawa S; Takahashi M; Hasegawa A; Kawazoe A; Masuishi T; Mizutani H; Kiyohara Y
Support Care Cancer; 2022 May; 30(5):4497-4504. PubMed ID: 35113224
[TBL] [Abstract][Full Text] [Related]
31. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.
Dotan E; Devarajan K; D'Silva AJ; Beck A; Kloth DD; Cohen SJ; Denlinger C
Clin Colorectal Cancer; 2014 Sep; 13(3):192-8. PubMed ID: 25074246
[TBL] [Abstract][Full Text] [Related]
32. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy.
Ramírez-Daffós P; Jiménez-Orozco E; Bolaños M; González Astorga B; Rubiales S; Ceballos-Barbancho E; Rodríguez García JM; Reina JJ
Support Care Cancer; 2022 Oct; 30(10):8081-8088. PubMed ID: 35776185
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
35. Effects of Sex and Seasonal Climatic Changes on the Risk of Incidence of Anti-EGFR Therapy-Induced Rash in Cancer Patients: A Retrospective Study.
Arai T; Fujita Y; Imai H; Matsumoto H; Yamazaki M; Hiruta E; Suzuki Y; Ojima H; Hosaka H; Minato K; Saito T
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441007
[No Abstract] [Full Text] [Related]
36. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
39. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]